Effect of empagliflozin on chronic eGFR slopes
KIDNEY FAILURE
Overall, allocation to empagliflozin slowed the rate of decline in eGFR
from 2 months to final follow-up (the ‘chronic slope’) by
1·37 (95% CI 1·16–1·59)
mL/min/1·73mSmaller absolute differences between empagliflozin and placebo in
chronic slopes were observed in the lowest uACR categories, but the mean rate of
decline was also substantially lower in these groups. As a result, when
comparing the Relative differences in chronic slope were generally similar across
other subgroups with statistical evidence for some effect modification by age,
glycated haemoglobin and 5-year risk of kidney failure, although clear benefits
remained in all subcategories of these subgroups (